料附件：
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c5a00ca-d662-46e6-b9ac-a07e9cfcc0a8&version=1
----------------------------------------------------
Ryplazim(plasminogen, human-tmvh)plasminogen, the treatment of congenital plasminogen deficiency(C-PLGD).
PLGD (Plasminogen deficiency) can be translated as Plasminogen Deficiency, Plasminogen Deficiency, Plasminogen Deficiency, Congenital Plasminogen Deficiency.
On June 04, 2021, the US Food and Drug Administration announced the approval of Liminal BioSciences' Ryplazim (plasminogen, human-tmvh)for the treatment of Type 1plasminogen deficiency(T1-PLGD)patients.
PRINCIPAL DISPLAY PANEL - 68.8 MG VIAL LABEL
NDC 70573-099-01
68.8mg/vial
plasminogen, human-tvmh
Ryplazim®
For Intravenous Use Only
Sterile, Preservative-Free
Single-Dose Vial
Discard Unused Portion
US LIC. NO.: 2065
|
